← All trials
NCT07307638
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 28, 2024
- Primary completion
- Jun 14, 2025
- Completion date
- Jun 24, 2025
- First posted
- Dec 29, 2025
- Last posted
- Dec 29, 2025
- Enrollment
- 94
- Arms / groups
- 12 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Beijing QL Biopharmaceutical Co.,LtdLead sponsor
- Anhui Medical UniversityOfficial
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.